Daina Graybosch
Stock Analyst at Leerink Partners
(1.31)
# 3,645
Out of 5,081 analysts
98
Total ratings
42.65%
Success rate
-7.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $0.51 | +290.55% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.90 | +5.26% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.71 | +183.29% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $2.05 | +241.46% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $18.37 | -34.68% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $102.27 | +16.36% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.27 | +279.51% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $72.94 | -46.53% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $57.13 | -21.23% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.08 | +825.93% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $25.63 | +48.26% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.45 | +79.78% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $96.73 | +131.57% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.78 | +1,585.39% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.92 | +1,752.05% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.57 | +473.25% | 4 | Feb 25, 2022 |
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $0.51
Upside: +290.55%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.90
Upside: +5.26%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.71
Upside: +183.29%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $2.05
Upside: +241.46%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $18.37
Upside: -34.68%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $102.27
Upside: +16.36%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.27
Upside: +279.51%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $72.94
Upside: -46.53%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $57.13
Upside: -21.23%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.08
Upside: +825.93%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $25.63
Upside: +48.26%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.45
Upside: +79.78%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $96.73
Upside: +131.57%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $1.78
Upside: +1,585.39%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.92
Upside: +1,752.05%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.57
Upside: +473.25%